{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:57:57Z","timestamp":1762300677565,"version":"3.41.2"},"reference-count":399,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780443241147"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020566","name":"Institute of Advanced Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020566","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.pmbts.2024.03.035","type":"book-chapter","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T17:38:12Z","timestamp":1716399492000},"page":"249-319","source":"Crossref","is-referenced-by-count":3,"title":["Drug repurposing for neurodegenerative diseases"],"prefix":"10.1016","member":"78","reference":[{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1007315","article-title":"Therapeutic drug repositioning with special emphasis on neurodegenerative diseases: threats and issues","volume":"13","author":"Kakoti","year":"2022","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib3","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3390\/ijms23031851","article-title":"A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of\u00a0nanotherapeutics","volume":"23","author":"Lamptey","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib4","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1186\/s12913-022-08272-z","article-title":"Drug repurposing: a systematic review on root causes, barriers and facilitators","volume":"22","author":"Krishnamurthy","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.768023","article-title":"Current drug repurposing strategies for rare neurodegenerative disorders","volume":"12","author":"Shah","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114239","article-title":"Drug repositioning: progress and challenges in drug discovery for various diseases","volume":"234","author":"Hua","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"9","key":"10.1016\/bs.pmbts.2024.03.035_bib7","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3390\/cancers12092694","article-title":"Applications of genome-wide screening and systems biology approaches in drug repositioning","volume":"12","author":"Mohammadi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib8","doi-asserted-by":"crossref","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics [published correction appears in Science 2002 Sep 27;297(5590):2209]. Science. 2002;297(5580):353\u2013356. https:\/\/doi.org\/10.1126\/science.1072994, PMID: 12130773.","DOI":"10.1126\/science.1072994"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3233\/JAD-2010-1221","article-title":"3rd. Alzheimer\u2019s disease and the amyloid-beta peptide","volume":"19","author":"Murphy","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.03.035_bib290","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes The Huntington\u2019s Disease Collaborative Research Group","volume":"72","author":"Mac Donald","year":"1993","journal-title":"Cell"},{"issue":"23","key":"10.1016\/bs.pmbts.2024.03.035_bib11","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2174\/092986708785909111","article-title":"Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease","volume":"15","author":"Gong","year":"2008","journal-title":"Curr Med Chem"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJMra1603471","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Brown","year":"2017","journal-title":"N Engl J Med"},{"issue":"9648","key":"10.1016\/bs.pmbts.2024.03.035_bib13","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104946","article-title":"Genetic architecture of common non-Alzheimer\u2019s disease dementias","volume":"142","author":"Guerreiro","year":"2020","journal-title":"Neurobiol Dis"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib15","unstructured":"Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. World Alzheimer Report 2015. The global impact of dementia: an analysis of prevalence, incidence, cost and trends (Doctoral dissertation, Alzheimer\u2019s disease international)."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13024-020-00391-7","article-title":"Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer\u2019s disease","volume":"15","author":"Guo","year":"2020","journal-title":"Mol Neurodegener"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.03.035_bib17","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The Amyloid-\u03b2 pathway in Alzheimer\u2019s disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"9533","key":"10.1016\/bs.pmbts.2024.03.035_bib18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer\u2019s disease","volume":"368","author":"Blennow","year":"2006","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002270","article-title":"APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases","volume":"14","author":"Lanoiselee","year":"2017","journal-title":"PLoS Med"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib20","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1471-4159.2006.04426.x","article-title":"A beta oligomers\u2014a decade of discovery","volume":"101","author":"Walsh","year":"2007","journal-title":"J Neurochem"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1582-4934.2009.00609.x","article-title":"Abeta aggregation and possible implications in Alzheimer\u2019s disease pathogenesis","volume":"13","author":"Bharadwaj","year":"2009","journal-title":"J Cell Mol Med"},{"issue":"11","key":"10.1016\/bs.pmbts.2024.03.035_bib22","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jalz.2015.01.005","article-title":"The aqueous phase of Alzheimer\u2019s disease brain contains assemblies built from \u223c4 and \u223c7 kDa A\u03b2 species","volume":"11","author":"Mc Donald","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"43","key":"10.1016\/bs.pmbts.2024.03.035_bib23","doi-asserted-by":"crossref","first-page":"14411","DOI":"10.1523\/JNEUROSCI.3537-10.2010","article-title":"Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils","volume":"30","author":"O\u2019Nuallain","year":"2010","journal-title":"J Neurosci"},{"issue":"14","key":"10.1016\/bs.pmbts.2024.03.035_bib24","doi-asserted-by":"crossref","first-page":"7722","DOI":"10.3390\/ijms23147722","article-title":"Dysfunction of mitochondria in Alzheimer\u2019s disease: ANT and VDAC interact with toxic proteins and aid to determine the fate of brain cells","volume":"23","author":"Atlante","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.03.035_bib25","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.bbadis.2013.10.015","article-title":"Oxidative stress and mitochondrial dysfunction in Alzheimer\u2019s disease","volume":"1842","author":"Wang","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib26","article-title":"Regulation of mitochondrial dysfunction induced cell apoptosis is a potential therapeutic strategy for herbal medicine to treat neurodegenerative diseases","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"issue":"28","key":"10.1016\/bs.pmbts.2024.03.035_bib27","doi-asserted-by":"crossref","first-page":"9090","DOI":"10.1523\/JNEUROSCI.1357-09.2009","article-title":"Impaired balance of mitochondrial fission and fusion in Alzheimer\u2019s disease","volume":"29","author":"Wang","year":"2009","journal-title":"J Neurosci"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib28","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1755-5949.2010.00177.x","article-title":"The role of tau in Alzheimer\u2019s disease and related disorders","volume":"17","author":"Medeiros","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1750-1326-4-13","article-title":"The role of tau in neurodegeneration","volume":"4","author":"Gendron","year":"2009","journal-title":"Mol Neurodegener"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.03.035_bib30","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2174\/156720508786898442","article-title":"Tau oligomerization: a role for tau aggregation intermediates linked to neurodegeneration","volume":"5","author":"Sahara","year":"2008","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib31","first-page":"271","article-title":"Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2","volume":"387","author":"Neve","year":"1986","journal-title":"Brain Res"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib32","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","article-title":"Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer\u2019s disease","volume":"3","author":"Goedert","year":"1989","journal-title":"Neuron"},{"issue":"16","key":"10.1016\/bs.pmbts.2024.03.035_bib33","doi-asserted-by":"crossref","first-page":"9548","DOI":"10.1073\/pnas.1633508100","article-title":"Differential regulation of microtubule dynamics by three- and four-repeat tau: implications for the onset of neurodegenerative disease","volume":"100","author":"Panda","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib34","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3233\/JAD-2010-101155","article-title":"MAPT isoforms: differential transcriptional profiles related to 3R and 4R splice variants","volume":"22","author":"Chen","year":"2010","journal-title":"J Alzheimers Dis"},{"issue":"5866","key":"10.1016\/bs.pmbts.2024.03.035_bib35","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1126\/science.1152993","article-title":"Differential regulation of dynein and kinesin motor proteins by tau","volume":"319","author":"Dixit","year":"2008","journal-title":"Science"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/jb\/mvw009","article-title":"Microglia in central nervous system repair after injury","volume":"159","author":"Jin","year":"2016","journal-title":"J Biochem"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib37","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/187152710791012071","article-title":"Microglia and inflammation in Alzheimer\u2019s disease","volume":"9","author":"Mandrekar-Colucci","year":"2010","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrn2038","article-title":"Microglia-mediated neurotoxicity: uncovering the molecular mechanisms","volume":"8","author":"Block","year":"2007","journal-title":"Nat Rev Neurosci"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.03.035_bib39","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/nn.4631","article-title":"Microglia turnover with aging and in an Alzheimer\u2019s model via long-term in vivo single-cell imaging","volume":"20","author":"F\u00fcger","year":"2017","journal-title":"Nat Neurosci"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib40","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.celrep.2018.04.001","article-title":"P2Y12R-Dependent translocation mechanisms gate the changing microglial landscape","volume":"23","author":"Eyo","year":"2018","journal-title":"Cell Rep"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.03.035_bib41","first-page":"136","article-title":"Role of pro-inflammatory cytokines released from microglia in Alzheimer\u2019s disease","volume":"3","author":"Wang","year":"2015","journal-title":"Ann Transl Med"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.03.035_bib42","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1212\/01.WNL.0000140706.52798.BE","article-title":"Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study","volume":"63","author":"de Lau","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib43","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev-pharmtox-011613-135937","article-title":"Environmental toxins and Parkinson\u2019s disease","volume":"54","author":"Goldman","year":"2014","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"5321","key":"10.1016\/bs.pmbts.2024.03.035_bib44","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"issue":"22","key":"10.1016\/bs.pmbts.2024.03.035_bib45","doi-asserted-by":"crossref","first-page":"14498","DOI":"10.3390\/ijms232214498","article-title":"Protein misfolding and aggregation in the brain: common pathogenetic pathways in neurodegenerative and mental disorders","volume":"23","author":"Ochneva","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib46","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00401-012-1004-6","article-title":"Protein degradation pathways in Parkinson\u2019s disease: curse or blessing","volume":"124","author":"Ebrahimi-Fakhari","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib47","first-page":"38","article-title":"Mitochondrial dysfunction in Parkinson\u2019s disease-cause or consequence?","volume":"8","author":"Chen","year":"2019","journal-title":"Biology (Basel)"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pneurobio.2013.04.004","article-title":"Mitochondrial dysfunction and oxidative stress in Parkinson\u2019s disease","volume":"106\u2013107","author":"Subramaniam","year":"2013","journal-title":"Prog Neurobiol"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib49","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3233\/JPD-130230","article-title":"The role of oxidative stress in Parkinson\u2019s disease","volume":"3","author":"Dias","year":"2013","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib50","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7934442","article-title":"Targeting oxidative stress mechanisms to treat Alzheimer\u2019s and Parkinson\u2019s disease: a critical review","volume":"2022","author":"Aborode","year":"2022","journal-title":"Oxid Med Cell Longev"},{"issue":"6676","key":"10.1016\/bs.pmbts.2024.03.035_bib51","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/33416","article-title":"Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism","volume":"392","author":"Kitada","year":"1998","journal-title":"Nature"},{"issue":"5674","key":"10.1016\/bs.pmbts.2024.03.035_bib52","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.1096284","article-title":"Hereditary early-onset Parkinson\u2019s disease caused by mutations in PINK1","volume":"304","author":"Valente","year":"2004","journal-title":"Science"},{"issue":"5604","key":"10.1016\/bs.pmbts.2024.03.035_bib53","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1126\/science.1077209","article-title":"Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism","volume":"299","author":"Bonifati","year":"2003","journal-title":"Science"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib54","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","article-title":"Cloning of the gene containing mutations that cause PARK8-linked Parkinson\u2019s disease","volume":"44","author":"Pais\u00e1n-Ru\u00edz","year":"2004","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib55","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/bs.pmbts.2024.03.035_bib56","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","article-title":"Inflammation and immune dysfunction in Parkinson disease","volume":"22","author":"Tansey","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib57","doi-asserted-by":"crossref","first-page":"a028936","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple sclerosis pathology","volume":"8","author":"Lassmann","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"41","key":"10.1016\/bs.pmbts.2024.03.035_bib58","doi-asserted-by":"crossref","first-page":"9799","DOI":"10.1523\/JNEUROSCI.1787-16.2017","article-title":"Parkinson\u2019s disease is not simply a prion disorder","volume":"37","author":"Surmeier","year":"2017","journal-title":"J Neurosci"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.03.035_bib59","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1093\/brain\/awad064","article-title":"Impaired dopamine release in Parkinson\u2019s disease","volume":"146","author":"Cramb","year":"2023","journal-title":"Brain"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib60","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","article-title":"Huntington disease","volume":"57","author":"Vonsattel","year":"1998","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.03.035_bib61","doi-asserted-by":"crossref","first-page":"a007476","DOI":"10.1101\/cshperspect.a007476","article-title":"Huntington\u2019s disease","volume":"3","author":"Finkbeiner","year":"2011","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0888-7543(90)90442-W","article-title":"Physical maps of 4p16.3, the area expected to contain the Huntington disease mutation","volume":"6","author":"Bu\u0107an","year":"1990","journal-title":"Genomics"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib63","first-page":"65","article-title":"The biological function of the Huntingtin protein and its relevance to Huntington\u2019s disease pathology","volume":"5","author":"Schulte","year":"2011","journal-title":"Curr Trends Neurol"},{"issue":"11 Suppl","key":"10.1016\/bs.pmbts.2024.03.035_bib64","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0166-2236(00)01997-4","article-title":"Huntington\u2019s disease: new hope for therapeutics","volume":"24","author":"McMurray","year":"2001","journal-title":"Trends Neurosci"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.03.035_bib65","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3390\/brainsci12101389","article-title":"Pathogenesis of Huntington\u2019s disease: an emphasis on molecular pathways and prevention by natural remedies","volume":"12","author":"Irfan","year":"2022","journal-title":"Brain Sci"},{"issue":"9557","key":"10.1016\/bs.pmbts.2024.03.035_bib66","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib67","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.phrs.2015.08.002","article-title":"Transcriptional dysregulation in Huntington\u2019s disease: the role of histone deacetylases","volume":"100","author":"Sharma","year":"2015","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib68","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3233\/JHD-180331","article-title":"Transcriptional regulation of the huntingtin gene","volume":"7","author":"Thomson","year":"2018","journal-title":"J Huntingtons Dis"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib69","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/JHD-160205","article-title":"Oxidative stress and Huntington\u2019s disease: the good, the bad, and the ugly","volume":"5","author":"Kumar","year":"2016","journal-title":"J Huntingtons Dis"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.825086","article-title":"Microglia and neuroinflammation: crucial pathological mechanisms in traumatic brain injury-induced neurodegeneration","volume":"14","author":"Shao","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.03.035_bib71","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease","volume":"205","author":"Bj\u00f6rkqvist","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib72","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/541259","article-title":"The role of the immune system in Huntington\u2019s disease","volume":"2013","author":"Ellrichmann","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib73","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.coph.2015.09.008","article-title":"Disruption of immune cell function by mutant huntingtin in Huntington\u2019s disease pathogenesis","volume":"26","author":"Andre","year":"2016","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib74","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fnagi.2017.00193","article-title":"Microglial activation in the Pathogenesis of Huntington\u2019s disease","volume":"9","author":"Yang","year":"2017","journal-title":"Front Aging Neurosci"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.03.035_bib75","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/14656566.2021.1876666","article-title":"State-of-the-art pharmacological approaches to reduce chorea in Huntington\u2019s disease","volume":"22","author":"Gibson","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib76","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3233\/JHD-200404","article-title":"The clinical features and progression of late-onset versus younger-onset in an adult cohort of Huntington\u2019s disease patients","volume":"9","author":"Anil","year":"2020","journal-title":"J Huntingtons Dis"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.03.035_bib77","article-title":"Management of agitation in Huntington\u2019s disease: a review of the literature","volume":"12","author":"Rossi","year":"2020","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib78","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40259-022-00519-9","article-title":"Antisense oligonucleotide therapy: from design to the Huntington disease clinic","volume":"36","author":"Rook","year":"2022","journal-title":"BioDrugs"},{"issue":"16","key":"10.1016\/bs.pmbts.2024.03.035_bib79","doi-asserted-by":"crossref","first-page":"8363","DOI":"10.3390\/ijms22168363","article-title":"New avenues for the treatment of Huntington\u2019s disease","volume":"22","author":"Kim","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib80","first-page":"1","article-title":"Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy","volume":"19","author":"Ghasemi","year":"2017","journal-title":"Cell J"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib81","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3390\/cimb45020094","article-title":"Multiple sclerosis: inflammatory and neuroglial aspects","volume":"45","author":"Papiri","year":"2023","journal-title":"Curr Issues Mol Biol"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib82","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2174\/157015911796557911","article-title":"Multiple sclerosis: pathogenesis and treatment","volume":"9","author":"Loma","year":"2011","journal-title":"Curr Neuropharmacol"},{"issue":"1\u20132","key":"10.1016\/bs.pmbts.2024.03.035_bib83","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jneuroim.2009.10.015","article-title":"Role of the innate immune system in the pathogenesis of multiple sclerosis","volume":"221","author":"Gandhi","year":"2010","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib84","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12974-022-02663-z","article-title":"Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis","volume":"19","author":"Liu","year":"2022","journal-title":"J Neuroinflamm"},{"issue":"9","key":"10.1016\/bs.pmbts.2024.03.035_bib85","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrneurol.2010.112","article-title":"Targeting dendritic cells to treat multiple sclerosis","volume":"6","author":"Comabella","year":"2010","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.03.035_bib86","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.4049\/jimmunol.178.10.6092","article-title":"Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis","volume":"178","author":"Duddy","year":"2007","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib87","first-page":"250","article-title":"Numerical status of CD4(+)CD25(+)FoxP3(+) and CD8(+)CD28(\u2013) regulatory T cells in multiple sclerosis","volume":"17","author":"Kouchaki","year":"2014","journal-title":"Iran J Basic Med Sci"},{"issue":"suppl 1","key":"10.1016\/bs.pmbts.2024.03.035_bib88","first-page":"S2","article-title":"Multiple sclerosis immunology: the healthy immune system vs the MS immune system","volume":"74","author":"Kasper","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib89","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3389\/fimmu.2016.00382","article-title":"Fas-fas ligand: checkpoint of T Cell functions in multiple sclerosis","volume":"7","author":"Volpe","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib90","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/5584_2018_247","article-title":"Stem Cell Therapy for Multiple Sclerosis","volume":"1084","author":"Genc","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib91","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-022-00932-0","article-title":"The secretion profile of mesenchymal stem cells and potential applications in treating human diseases","volume":"7","author":"Han","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"10.1016\/bs.pmbts.2024.03.035_bib92","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.tips.2020.06.009","article-title":"Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential","volume":"41","author":"Song","year":"2020","journal-title":"Trends Pharmacol Sci"},{"issue":"1\u20132","key":"10.1016\/bs.pmbts.2024.03.035_bib93","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jns.2005.03.009","article-title":"Vitamin B12, demyelination, remyelination and repair in multiple sclerosis","volume":"233","author":"Miller","year":"2005","journal-title":"J Neurol Sci"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib94","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.msard.2017.08.004","article-title":"Vitamin B12, folate, and homocysteine levels and multiple sclerosis: a meta-analysis","volume":"17","author":"Dardiotis","year":"2017","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.03.035_bib95","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/ene.14393","article-title":"Amyotrophic lateral sclerosis: a clinical review","volume":"27","author":"Masrori","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib96","doi-asserted-by":"crossref","unstructured":"Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis [published correction appears in Nat Rev Dis Primers. 2017 Oct 20;3:17085] Nat Rev Dis Primers. 2017;3:17071.\u00a0https:\/\/doi.org\/10.1038\/nrdp.2017.71, PMID: 28980624.","DOI":"10.1038\/nrdp.2017.85"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib97","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.nrl.2015.12.001","article-title":"Why do motor neurons degenerate? Actualization in the pathogenesis of amyotrophic lateral sclerosis. \u00bfPor qu\u00e9 degeneran las motoneuronas? Actualizaci\u00f3n en la patogenia de la esclerosis lateral amiotr\u00f3fica","volume":"34","author":"Riancho","year":"2019","journal-title":"Neurologia (Engl Ed)"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib98","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ana.24096","article-title":"SLALOM Group. Long-term survival in amyotrophic lateral sclerosis: a population-based study","volume":"75","author":"Pupillo","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib99","doi-asserted-by":"crossref","first-page":"371","DOI":"10.12688\/f1000research.10476.1","article-title":"What causes amyotrophic lateral sclerosis?","volume":"6","author":"Martin","year":"2017","journal-title":"F1000Res"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib100","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000351153","article-title":"Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature","volume":"41","author":"Chi\u00f2","year":"2013","journal-title":"Neuroepidemiology"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib101","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/B978-0-12-385883-2.00002-3","article-title":"The complex molecular biology of amyotrophic lateral sclerosis (ALS)","volume":"107","author":"Redler","year":"2012","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"5870","key":"10.1016\/bs.pmbts.2024.03.035_bib102","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1126\/science.1154584","article-title":"TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis","volume":"319","author":"Sreedharan","year":"2008","journal-title":"Science"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib103","doi-asserted-by":"crossref","unstructured":"Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis [published correction appears in Nature. 1993 Jul 22;364(6435):362]. Nature. 1993;362(6415):59\u201362. https:\/\/doi.org\/10.1038\/362059a0, PMID: 8446170.","DOI":"10.1038\/364362c0"},{"issue":"16","key":"10.1016\/bs.pmbts.2024.03.035_bib104","doi-asserted-by":"crossref","first-page":"9631","DOI":"10.1073\/pnas.95.16.9631","article-title":"Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant","volume":"95","author":"Williamson","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4 Suppl 2","key":"10.1016\/bs.pmbts.2024.03.035_bib105","first-page":"S54","article-title":"Mechanisms of selective motor neuron death in transgenic mouse models of motor neuron disease","volume":"47","author":"Cleveland","year":"1996","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/bs.pmbts.2024.03.035_bib106","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/nn.3230","article-title":"Divergent roles of ALS-linked proteins FUS\/TLS and TDP-43 intersect in processing long pre-mRNAs","volume":"15","author":"Lagier-Tourenne","year":"2012","journal-title":"Nat Neurosci"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib107","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mcn.2012.10.008","article-title":"Inflammation and neurovascular changes in amyotrophic lateral sclerosis","volume":"53","author":"Evans","year":"2013","journal-title":"Mol Cell Neurosci"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib108","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s11481-013-9489-x","article-title":"Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis","volume":"8","author":"Zhao","year":"2013","journal-title":"J Neuroimmune Pharmacol"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib109","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2741\/s149","article-title":"Inflammation and oxidative damage in Alzheimer\u2019s disease: friend or foe?","volume":"3","author":"Galimberti","year":"2011","journal-title":"Front Biosci (Sch Ed)"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib110","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0079-6123(10)84006-3","article-title":"Modeling neuroinflammatory pathogenesis of Parkinson\u2019s disease","volume":"184","author":"Barnum","year":"2010","journal-title":"Prog Brain Res"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib111","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1747-4949.2008.00222.x","article-title":"Immune and inflammatory responses to stroke: good or bad?","volume":"3","author":"McCombe","year":"2008","journal-title":"Int J Stroke"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.03.035_bib112","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2217\/nmt.14.34","article-title":"Frontotemporal dementia: diagnosis, deficits and management","volume":"4","author":"Bott","year":"2014","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib113","series-title":"StatPearls.","article-title":"Spinocerebellar Ataxia","author":"Bhandari","year":"2023"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib114","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11011-005-7910-8","article-title":"Wilson disease","volume":"20","author":"Kitzberger","year":"2005","journal-title":"Metab Brain Dis"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.03.035_bib115","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/2045125318759461","article-title":"Psychiatric manifestations in Wilson\u2019s disease: possibilities and difficulties for treatment","volume":"8","author":"Litwin","year":"2018","journal-title":"Ther Adv Psychopharmacol"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib116","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1208\/s12248-012-9390-1","article-title":"Drug repurposing: far beyond new targets for old drugs","volume":"14","author":"Oprea","year":"2012","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib117","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13046-017-0642-x","article-title":"Drug repurposing for the treatment of glioblastoma multiforme","volume":"36","author":"Abbruzzese","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"10.1016\/bs.pmbts.2024.03.035_bib118","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.2174\/0929867327666200831141337","article-title":"Perspectives on drug repurposing","volume":"28","author":"Schcolnik-Cabrera","year":"2021","journal-title":"Curr Med Chem"},{"issue":"9","key":"10.1016\/bs.pmbts.2024.03.035_bib119","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/jphp.13273","article-title":"Drug repositioning: a brief overview","volume":"72","author":"Jourdan","year":"2020","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib120","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrd2265","article-title":"High-throughput electronic biology: mining information for drug discovery","volume":"6","author":"Loging","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib121","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1021\/ci500670q","article-title":"Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic and molecular data","volume":"55","author":"Iwata","year":"2015","journal-title":"J Chem Inf Model"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib122","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fphar.2017.00298","article-title":"On the integration of in silico drug design methods for drug repurposing","volume":"8","author":"March-Vila","year":"2017","journal-title":"Front Pharmacol"},{"issue":"19","key":"10.1016\/bs.pmbts.2024.03.035_bib123","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1093\/bioinformatics\/btz156","article-title":"A new computational drug repurposing method using established disease-drug pair knowledge","volume":"35","author":"Saberian","year":"2019","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib124","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/jcmm.12447","article-title":"Pathway mapping and development of disease-specific biomarkers: protein-based network biomarkers","volume":"19","author":"Chen","year":"2015","journal-title":"J Cell Mol Med"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib125","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/648740","article-title":"Shared mechanisms of neurodegeneration in Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"2014","author":"Xie","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib126","article-title":"A review of current in silico methods for repositioning drugs and chemical compounds","volume":"11","author":"He","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib127","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bph.13798","article-title":"Drug repurposing from the perspective of pharmaceutical companies","volume":"175","author":"Cha","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib128","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.drudis.2013.11.005","article-title":"Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines","volume":"19","author":"Jin","year":"2014","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib129","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12859-023-05317-w","article-title":"Drug repurposing and prediction of multiple interaction types via graph embedding","volume":"24","author":"Amiri Souri","year":"2023","journal-title":"BMC Bioinforma"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib130","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41386-020-0752-6","article-title":"Signature-based approaches for informed drug repurposing: targeting CNS disorders","volume":"46","author":"Shukla","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib131","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/proteomes11040034","article-title":"Multi-Omics\u00a0integration for the design of novel therapies and the identification of novel biomarkers","volume":"11","author":"Ivanisevic","year":"2023","journal-title":"Proteomes"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib132","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-4939-9089-4_2","article-title":"High-throughput screening for drug combinations","volume":"1939","author":"Shinn","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib133","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cbpa.2021.06.001","article-title":"Recent advances in drug repurposing using machine learning","volume":"65","author":"Urbina","year":"2021","journal-title":"Curr Opin Chem Biol"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib134","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1039\/c2cs35357a","article-title":"Drug repositioning by structure-based virtual screening","volume":"42","author":"Ma","year":"2013","journal-title":"Chem Soc Rev"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib135","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3390\/ijms13010427","article-title":"Adaptation of high-throughput screening in drug discovery-toxicological screening tests","volume":"13","author":"Szyma\u0144ski","year":"2012","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.03.035_bib136","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41573-022-00472-w","article-title":"Phenotypic drug discovery: recent successes, lessons learned and new directions","volume":"21","author":"Vincent","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"33","key":"10.1016\/bs.pmbts.2024.03.035_bib137","doi-asserted-by":"crossref","first-page":"14621","DOI":"10.1073\/pnas.1000138107","article-title":"Discovery of drug mode of action and drug repositioning from transcriptional responses","volume":"107","author":"Iorio","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib138","first-page":"127","article-title":"Network pharmacology","author":"Chandran","year":"2017","journal-title":"Inno\u00a0Approaches Drug Discov"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib139","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbac229","article-title":"Network approaches for modeling the effect of drugs and diseases","volume":"23","author":"Rintala","year":"2022","journal-title":"Brief Bioinform"},{"issue":"15","key":"10.1016\/bs.pmbts.2024.03.035_bib140","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2174\/1568026617666161116143440","article-title":"Bioinformatics and drug discovery","volume":"17","author":"Xia","year":"2017","journal-title":"Curr Top Med Chem"},{"issue":"18","key":"10.1016\/bs.pmbts.2024.03.035_bib141","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.3390\/ijms20184331","article-title":"Molecular docking: shifting paradigms in drug discovery","volume":"20","author":"Pinzi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib142","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-0716-2305-3_5","article-title":"Biomedical literature mining for repurposing laboratory tests","volume":"2496","author":"Kuusisto","year":"2022","journal-title":"Methods Mol Biol"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.03.035_bib143","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug repurposing: a promising tool to accelerate the drug discovery process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov Today"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.03.035_bib144","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.03.035_bib145","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3390\/ph15080926","article-title":"Three-Dimensional in vitro cell culture models for efficient drug discovery: progress so far and future prospects","volume":"15","author":"Badr-Eldin","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib146","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/cts.13066","article-title":"3D cell culture models: drug pharmacokinetics, safety assessment, and regulatory consideration","volume":"14","author":"Wang","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib147","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3810\/pgm.2011.09.2475","article-title":"Key concepts of clinical trials: a narrative review","volume":"123","author":"Umscheid","year":"2011","journal-title":"Postgrad Med"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib148","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrd3375","article-title":"Trial watch: phase III and submission failures: 2007\u20132010","volume":"10","author":"Arrowsmith","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib149","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/bimj.201600084","article-title":"Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations","volume":"59","author":"Ursino","year":"2017","journal-title":"Biom J"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib150","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/med.21627","article-title":"Repurposing approved drugs on the pathway to novel therapies","volume":"40","author":"Schein","year":"2020","journal-title":"Med Res Rev"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.03.035_bib151","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib152","article-title":"Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications","volume":"2","author":"Murteira","year":"2014","journal-title":"J Mark Access Health Policy"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.03.035_bib153","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0289890","article-title":"Polypharmacology guided drug repositioning approach for SARS-CoV2","volume":"18","author":"Jamir","year":"2023","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib154","doi-asserted-by":"crossref","first-page":"60","DOI":"10.32607\/actanaturae.10925","article-title":"Promising Molecular targets for pharmacological therapy of neurodegenerative pathologies","volume":"12","author":"Neganova","year":"2020","journal-title":"Acta Naturae"},{"issue":"R2","key":"10.1016\/bs.pmbts.2024.03.035_bib155","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1093\/hmg\/ddy186","article-title":"Drug screening for human genetic diseases using iPSC models","volume":"27","author":"Elitt","year":"2018","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib156","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.3390\/ijms25042392","article-title":"Induced pluripotent stem cells in drug discovery and neurodegenerative disease modelling","volume":"25","author":"Beghini","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib157","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.stem.2013.01.008","article-title":"Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression","volume":"12","author":"Reinhardt","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib158","first-page":"567","article-title":"CRISPR\/Cas9 genome editing for neurodegenerative diseases","volume":"22","author":"Nouri Nojadeh","year":"2023","journal-title":"EXCLI J"},{"issue":"7601","key":"10.1016\/bs.pmbts.2024.03.035_bib159","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nature17939","article-title":"Parkinson-associated risk variant in distal enhancer of \u03b1-synuclein modulates target gene expression","volume":"533","author":"Soldner","year":"2016","journal-title":"Nature"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib160","article-title":"Applications of multi-omics analysis in human diseases","volume":"4","author":"Chen","year":"2023","journal-title":"MedComm (2020)"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.03.035_bib161","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1021\/acs.molpharmaceut.6b00248","article-title":"Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data","volume":"13","author":"Aliper","year":"2016","journal-title":"Mol Pharm"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib162","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1134\/S1068162023020139","article-title":"Drug repurposing: an effective tool in modern drug discovery","volume":"49","author":"Kulkarni","year":"2023","journal-title":"Russ J Bioorg Chem"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.03.035_bib163","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.mayocp.2012.04.017","article-title":"Ten common questions (and their answers) about off-label drug use","volume":"87","author":"Wittich","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"D1","key":"10.1016\/bs.pmbts.2024.03.035_bib164","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"13","key":"10.1016\/bs.pmbts.2024.03.035_bib165","doi-asserted-by":"crossref","first-page":"i232","DOI":"10.1093\/bioinformatics\/btn162","article-title":"Prediction of drug-target interaction networks from the integration of chemical and genomic spaces","volume":"24","author":"Yamanishi","year":"2008","journal-title":"Bioinformatics"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.03.035_bib166","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib167","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/1074-5521(94)90034-5","article-title":"Towards a pharmacological genetics","volume":"1","author":"Mitchison","year":"1994","journal-title":"Chem Biol"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib168","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/wsbm.147","article-title":"Drug repurposing and adverse event prediction using high-throughput literature analysis","volume":"3","author":"Deftereos","year":"2011","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib169","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2174\/156802611795429185","article-title":"Target validation: linking target and chemical properties to desired product profile","volume":"11","author":"Wyatt","year":"2011","journal-title":"Curr Top Med Chem"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.03.035_bib170","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2174\/138620703771981205","article-title":"Forward & reverse chemical genetics using SPOS-based combinatorial chemistry","volume":"6","author":"Thorpe","year":"2003","journal-title":"Comb Chem High Throughput Screen"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib171","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cbpa.2004.04.002","article-title":"Complex phenotypic assays in high-throughput screening","volume":"8","author":"Clemons","year":"2004","journal-title":"Curr Opin Chem Biol"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.03.035_bib172","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib173","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1021\/cb100294v","article-title":"Identification of direct protein targets of small molecules","volume":"6","author":"Lomenick","year":"2011","journal-title":"ACS Chem Biol"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib174","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12896-023-00815-4","article-title":"Target identification of small molecules: an overview of the current applications in drug discovery","volume":"23","author":"Tabana","year":"2023","journal-title":"BMC Biotechnol"},{"issue":"21","key":"10.1016\/bs.pmbts.2024.03.035_bib175","doi-asserted-by":"crossref","first-page":"13568","DOI":"10.3390\/ijms232113568","article-title":"Application of computational biology and artificial intelligence in drug design","volume":"23","author":"Zhang","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib176","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.chembiol.2004.05.001","article-title":"Target identification in chemical genetics: the (often) missing link","volume":"11","author":"Burdine","year":"2004","journal-title":"Chem Biol"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib177","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nchembio.2007.53","article-title":"Integrating high-content screening and ligand-target prediction to identify mechanism of action","volume":"4","author":"Young","year":"2008","journal-title":"Nat Chem Biol"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib178","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nchembio.1199","article-title":"Target identification and mechanism of action in chemical biology and drug discovery","volume":"9","author":"Schenone","year":"2013","journal-title":"Nat Chem Biol"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.03.035_bib179","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.tig.2018.04.004","article-title":"Genetic-driven druggable target identification and validation","volume":"34","author":"Floris","year":"2018","journal-title":"Trends Genet"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.03.035_bib180","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrg2364","article-title":"The art and design of genetic screens: RNA interference","volume":"9","author":"Boutros","year":"2008","journal-title":"Nat Rev Genet"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib181","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/bib\/bbz103","article-title":"Computational\/in silico methods in drug target and lead prediction","volume":"21","author":"Agamah","year":"2020","journal-title":"Brief Bioinform"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib182","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cbpa.2011.02.021","article-title":"The role of computational methods in the identification of bioactive compounds","volume":"15","author":"Glick","year":"2011","journal-title":"Curr Opin Chem Biol"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.03.035_bib183","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jprot.2011.05.011","article-title":"From in silico target prediction to multi-target drug design: current databases, methods and applications","volume":"74","author":"Koutsoukas","year":"2011","journal-title":"J Proteomics"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib184","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/bs.adgen.2015.11.004","article-title":"Integrative analysis of multi-omics data for discovery and functional studies of complex human diseases","volume":"93","author":"Sun","year":"2016","journal-title":"Adv Genet"},{"issue":"9","key":"10.1016\/bs.pmbts.2024.03.035_bib185","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.tips.2023.06.010","article-title":"AI-powered therapeutic target discovery","volume":"44","author":"Pun","year":"2023","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib186","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9836256","article-title":"Onco-multi-OMICS approach: a new frontier in cancer research","volume":"2018","author":"Chakraborty","year":"2018","journal-title":"Biomed Res Int"},{"issue":"1\u20132","key":"10.1016\/bs.pmbts.2024.03.035_bib187","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0092-8240(05)80006-0","article-title":"A logical calculus of the ideas immanent in nervous activity. 1943","volume":"52","author":"McCulloch","year":"1990","journal-title":"Bull Math Biol"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib188","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s10462-021-10058-4","article-title":"Machine learning in drug discovery: a review","volume":"55","author":"Dara","year":"2022","journal-title":"Artif Intell Rev"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.03.035_bib189","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.drudis.2022.03.006","article-title":"Structure-based drug repurposing: traditional and advanced AI\/ML-aided methods","volume":"27","author":"Choudhury","year":"2022","journal-title":"Drug Discov Today"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.03.035_bib190","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e17575","article-title":"AI in drug discovery and its clinical relevance","volume":"9","author":"Qureshi","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib191","doi-asserted-by":"crossref","DOI":"10.1177\/1179573520907397","article-title":"Current and future treatments in Alzheimer disease: an update","volume":"12","author":"Yiannopoulou","year":"2020","journal-title":"J Cent Nerv Syst Dis"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib192","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4103\/jehp.jehp_451_22","article-title":"Therapeutic and medicinal effects of snowdrop (Galanthus spp.) in Alzheimer\u2019s disease: a review","volume":"12","author":"Babashpour-Asl","year":"2023","journal-title":"J Educ Health Promot"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib193","first-page":"CD001747","article-title":"Galantamine for Alzheimer\u2019s disease","author":"Olin","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib194","doi-asserted-by":"crossref","unstructured":"Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer\u2019s disease: multicentre randomised controlled trial. Galantamine International-1 Study Group [published correction appears in BMJ 2001 Feb 17;322(7283):405]. BMJ. 2000;321(7274):1445\u20131449. https:\/\/doi.org\/10.1136\/bmj.321.7274.1445, PMID: 11110737.","DOI":"10.1136\/bmj.321.7274.1445"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.03.035_bib195","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib196","first-page":"CD001747","article-title":"Galantamine for Alzheimer\u2019s disease and mild cognitive impairment","volume":"2006","author":"Loy","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib197","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1741-7015-11-81","article-title":"Striking reduction of amyloid plaque burden in an Alzheimer\u2019s mouse model after chronic administration of carmustine","volume":"11","author":"Hayes","year":"2013","journal-title":"BMC Med"},{"issue":"9","key":"10.1016\/bs.pmbts.2024.03.035_bib198","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2174\/1389200218666170607101622","article-title":"Repurposed drugs as potential therapeutic candidates for the management of Alzheimer\u2019s disease","volume":"18","author":"Shoaib","year":"2017","journal-title":"Curr Drug Metab"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib199","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.4161\/hv.23875","article-title":"Refinement of a DNA based Alzheimer\u2019s disease epitope vaccine in rabbits.","volume":"9","author":"Ghochikyan","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"14B","key":"10.1016\/bs.pmbts.2024.03.035_bib200","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1093\/nar\/16.14.6779","article-title":"Formation of covalent complexes between human O6-alkylguanine-DNA alkyltransferase and BCNU-treated defined length synthetic oligodeoxynucleotides","volume":"16","author":"Brent","year":"1988","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib201","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2147\/NDT.S61309","article-title":"The emerging role of bexarotene in the treatment of Alzheimer\u2019s disease: current evidence.","volume":"11","author":"Tousi","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib202","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12974-019-1432-5","article-title":"Activation of retinoid X receptor by bexarotene attenuates neuroinflammation via PPAR\u03b3\/SIRT6\/FoxO3a pathway after subarachnoid hemorrhage in rats","volume":"16","author":"Zuo","year":"2019","journal-title":"J Neuroinflammation"},{"issue":"21","key":"10.1016\/bs.pmbts.2024.03.035_bib203","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.3390\/cells12212575","article-title":"Development of bexarotene analogs for treating cutaneous T-Cell lymphomas","volume":"12","author":"Warda","year":"2023","journal-title":"Cells"},{"issue":"6075","key":"10.1016\/bs.pmbts.2024.03.035_bib204","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1126\/science.1217697","article-title":"ApoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models","volume":"335","author":"Cramer","year":"2012","journal-title":"Science"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102021","article-title":"The novel function of bexarotene for neurological diseases","volume":"90","author":"Liu","year":"2023","journal-title":"Ageing Res Rev"},{"issue":"6135","key":"10.1016\/bs.pmbts.2024.03.035_bib206","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233937","article-title":"Comment on ApoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models","volume":"340","author":"Tesseur","year":"2013","journal-title":"Science"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib207","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.trci.2016.06.001","article-title":"A randomized controlled study to evaluate the effect of bexarotene on amyloid-\u03b2 and apolipoprotein E metabolism in healthy subjects","volume":"2","author":"Ghosal","year":"2016","journal-title":"Alzheimers Dement (N Y"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.03.035_bib208","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223578","article-title":"Bexarotene therapy ameliorates behavioral deficits and induces functional and molecular changes in very-old Triple Transgenic Mice model of Alzheimer\u00b4s disease","volume":"14","author":"Mu\u00f1oz-Cabrera","year":"2019","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.03.035_bib209","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1248\/bpb.b12-00314","article-title":"Tamibarotene: a candidate retinoid drug for Alzheimer\u2019s disease","volume":"35","author":"Fukasawa","year":"2012","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib210","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3233\/JAD-132720","article-title":"Cooperative therapeutic action of retinoic acid receptor and retinoid x receptor agonists in a mouse model of Alzheimer\u2019s disease","volume":"42","author":"Kawahara","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib211","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/bjh.13607","article-title":"Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide","volume":"171","author":"Sanford","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib212","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s12035-021-02709-y","article-title":"Retinoid X receptor: cellular and biochemical roles of nuclear receptor with a focus on neuropathological involvement","volume":"59","author":"Sharma","year":"2022","journal-title":"Mol Neurobiol"},{"issue":"21","key":"10.1016\/bs.pmbts.2024.03.035_bib213","doi-asserted-by":"crossref","first-page":"13870","DOI":"10.1021\/acsomega.1c01526","article-title":"Therapeutic targeting of repurposed anticancer drugs in Alzheimer\u2019s disease: using the multiomics approach","volume":"6","author":"Advani","year":"2021","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib214","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-021-00831-6","article-title":"Anticancer drugs repurposed for Alzheimer\u2019s disease: a systematic review","volume":"13","author":"Ancidoni","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib215","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.phrs.2019.03.014","article-title":"Expanding spectrum of anticancer drug, imatinib, in the disorders affecting brain and spinal cord","volume":"143","author":"Kumar","year":"2019","journal-title":"Pharmacol Res"},{"issue":"5 Suppl","key":"10.1016\/bs.pmbts.2024.03.035_bib216","first-page":"S374","article-title":"Imatinib treatment and A\u03b242 in humans","volume":"10","author":"Olsson","year":"2014","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib217","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1074\/jbc.M112.370924","article-title":"The role of \u03b3-secretase activating protein (GSAP) and imatinib in the regulation of \u03b3-secretase activity and amyloid-\u03b2 generation","volume":"288","author":"Hussain","year":"2013","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib218","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1046\/j.1471-4159.2001.00046.x","article-title":"Activation and redistribution of c-jun N-terminal kinase\/stress activated protein kinase in degenerating neurons in Alzheimer\u2019s disease","volume":"76","author":"Zhu","year":"2001","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib219","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056586","article-title":"Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response","volume":"8","author":"Adzemovic","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib220","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s13063-021-05404-4","article-title":"An Investigation of Levetiracetam in Alzheimer\u2019s Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study","volume":"22","author":"Sen","year":"2021","journal-title":"Trials"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib221","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.888784","article-title":"Levetiracetam alleviates cognitive decline in Alzheimer\u2019s disease animal model by ameliorating the dysfunction of the neuronal network","volume":"14","author":"Zheng","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.03.035_bib222","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1021\/acs.jproteome.1c00180","article-title":"Levetiracetam treatment normalizes levels of presynaptic endocytosis machinery and restores nonamyloidogenic APP processing in App Knock-in Mice","volume":"20","author":"Rao","year":"2021","journal-title":"J Proteome Res"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib223","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1336026","article-title":"Levetiracetam modulates brain metabolic networks and transcriptomic signatures in the 5XFAD mouse model of Alzheimer\u2019s disease","volume":"17","author":"Burton","year":"2024","journal-title":"Front Neurosci"},{"issue":"42","key":"10.1016\/bs.pmbts.2024.03.035_bib224","doi-asserted-by":"crossref","first-page":"E2895","DOI":"10.1073\/pnas.1121081109","article-title":"Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer\u2019s disease model","volume":"109","author":"Sanchez","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/bs.pmbts.2024.03.035_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsps.2023.101728","article-title":"Impact of levetiracetam on cognitive impairment, neuroinflammation, oxidative stress, and neuronal apoptosis caused by lipopolysaccharides in rats","volume":"31","author":"Mani","year":"2023","journal-title":"Saudi Pharm J"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib226","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/nedt.2007.3.2.245","article-title":"Memantine: efficacy and safety in mild-to-severe Alzheimer\u2019s disease","volume":"3","author":"Tampi","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib227","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/ibra.12098","article-title":"Basic information about memantine and its treatment of Alzheimer\u2019s disease and other clinical applications","volume":"9","author":"Tang","year":"2023","journal-title":"Ibrain"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.03.035_bib228","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2174\/156720512801322564","article-title":"N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer\u2019s disease, vascular dementia and Parkinson\u2019s disease","volume":"9","author":"Olivares","year":"2012","journal-title":"Curr Alzheimer Res"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib229","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3233\/JAD-160763","article-title":"Role of glutamate and NMDA receptors in Alzheimer\u2019s disease","volume":"57","author":"Wang","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib230","doi-asserted-by":"crossref","first-page":"344","DOI":"10.4103\/0972-2327.179971","article-title":"Evaluating the efficacy of memantine on improving cognitive functions in epileptic patients receiving anti-epileptic drugs: a double-blind placebo-controlled clinical trial (Phase IIIb pilot study)","volume":"19","author":"Marimuthu","year":"2016","journal-title":"Ann Indian Acad Neurol"},{"issue":"14","key":"10.1016\/bs.pmbts.2024.03.035_bib231","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer\u2019s disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib232","article-title":"Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer\u2019s dementia","volume":"7","author":"Matthews","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib398","first-page":"195","article-title":"Donepezil in Alzheimer\u2019s disease: an evidence-based review of its impact on clinical and economic outcomes.","volume":"1","author":"Knowles","year":"2006","journal-title":"Core Evid"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.03.035_bib233","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.3390\/molecules26123724","article-title":"Role of monoamine oxidase activity in alzheimer\u2019s disease: an insight into the therapeutic potential of inhibitors","volume":"26","author":"Behl","year":"2021","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib234","first-page":"303","article-title":"Donepezil in Alzheimer\u2019s disease: from conventional trials to pharmacogenetics","volume":"3","author":"Cacabelos","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.03.035_bib235","first-page":"CD001190","article-title":"Donepezil for dementia due to Alzheimer\u2019s disease","volume":"6","author":"Birks","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.03.035_bib236","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1179\/1743132813Y.0000000295","article-title":"The effects of valsartan on cognitive deficits induced by aluminum trichloride and d-galactose in mice","volume":"36","author":"Yang","year":"2014","journal-title":"Neurol Res"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib237","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.brainresbull.2009.09.003","article-title":"Valproic acid as a promising agent to combat Alzheimer\u2019s disease","volume":"81","author":"Zhang","year":"2010","journal-title":"Brain Res Bull"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.03.035_bib238","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X17666181227165722","article-title":"Valproic acid and epilepsy: from molecular mechanisms to clinical evidences","volume":"17","author":"Romoli","year":"2019","journal-title":"Curr Neuropharmacol"},{"issue":"11","key":"10.1016\/bs.pmbts.2024.03.035_bib239","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/cns.12445","article-title":"Valproic acid modifies synaptic structure and accelerates neurite outgrowth via the glycogen synthase Kinase-3\u03b2 signaling pathway in an Alzheimer\u2019s disease model","volume":"21","author":"Long","year":"2015","journal-title":"CNS Neurosci Ther"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.03.035_bib240","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1084\/jem.20081588","article-title":"Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer\u2019s disease mouse models.","volume":"205","author":"Qing","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib241","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1137197","article-title":"Neuroprotective effect of angiotensin II receptor blockers on the risk of incident Alzheimer\u2019s disease: a nationwide population-based cohort study","volume":"15","author":"Lee","year":"2023","journal-title":"Front Aging Neurosci"},{"issue":"11","key":"10.1016\/bs.pmbts.2024.03.035_bib242","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1172\/JCI31547","article-title":"Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease","volume":"117","author":"Wang","year":"2007","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/bs.pmbts.2024.03.035_bib243","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/mds.20243","article-title":"Levodopa in the treatment of Parkinson\u2019s disease: current controversies","volume":"19","author":"Olanow","year":"2004","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.03.035_bib244","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2174\/1570159X15666170510143821","article-title":"Levodopa in Parkinson\u2019s Disease: Current Status and Future Developments","volume":"16","author":"Tambasco","year":"2018","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib245","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3233\/JPD-130186","article-title":"Levodopa in the treatment of Parkinson\u2019s disease: current status and new developments","volume":"3","author":"Salat","year":"2013","journal-title":"J Parkinsons Dis"},{"issue":"980","key":"10.1016\/bs.pmbts.2024.03.035_bib246","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/pgmj.2006.054759","article-title":"Levodopa-induced dyskinesia in Parkinson\u2019s disease: clinical features, pathogenesis, prevention and treatment","volume":"83","author":"Thanvi","year":"2007","journal-title":"Postgrad Med J"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib247","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2174\/1570159X16666180905094123","article-title":"Neuroregeneration in Parkinson\u2019s disease: from proteins to small molecules","volume":"17","author":"Sidorova","year":"2019","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib248","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/archneurol.2009.287","article-title":"Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease","volume":"67","author":"Brodsky","year":"2010","journal-title":"Arch Neurol"},{"issue":"13","key":"10.1016\/bs.pmbts.2024.03.035_bib249","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.3390\/jcm12134427","article-title":"Levodopa-Induced dyskinesias in Parkinson\u2019s disease: an overview on pathophysiology, clinical manifestations, therapy management strategies and future directions","volume":"12","author":"di Biase","year":"2023","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.03.035_bib250","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","article-title":"Amantadine in the treatment of Parkinson\u2019s disease and other movement disorders","volume":"20","author":"Rascol","year":"2021","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib251","first-page":"CD003467","article-title":"Amantadine for dyskinesia in Parkinson\u2019s disease","volume":"2003","author":"Crosby","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"10.1016\/bs.pmbts.2024.03.035_bib252","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1523\/JNEUROSCI.4262-04.2005","article-title":"Amantadine inhibits NMDA receptors by accelerating channel closure during channel block","volume":"25","author":"Blanpied","year":"2005","journal-title":"J Neurosci"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib253","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/mds.870130507","article-title":"Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys","volume":"13","author":"Blanchet","year":"1998","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib254","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson\u2019s disease","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib255","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.996217","article-title":"Nilotinib in Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"14","author":"Xie","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib256","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","article-title":"Efficacy of nilotinib in patients with moderately advanced Parkinson disease: a randomized clinical trial","volume":"78","author":"Simuni","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib257","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12974-022-02549-0","article-title":"Nilotinib modulates LPS-induced cognitive impairment and neuroinflammatory responses by regulating P38\/STAT3 signaling","volume":"19","author":"Kim","year":"2022","journal-title":"J Neuroinflamm"},{"issue":"16","key":"10.1016\/bs.pmbts.2024.03.035_bib258","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","article-title":"Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of \u03b1-synuclein in Parkinson\u2019s disease models","volume":"22","author":"Hebron","year":"2013","journal-title":"Hum Mol Genet"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.03.035_bib259","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3390\/metabo12121225","article-title":"Alteration of autophagy and glial activity in nilotinib-treated Huntington\u2019s disease patients","volume":"12","author":"Anderson","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib260","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.574652","article-title":"Zonisamide for the treatment of Parkinson disease: a current update","volume":"14","author":"Li","year":"2020","journal-title":"Front Neurosci"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib261","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1756285609338501","article-title":"A review of the use of zonisamide in Parkinson\u2019s disease","volume":"2","author":"Bermejo","year":"2009","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib262","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/wnf.0b013e3180413d7d","article-title":"Clinical pharmacology and mechanism of action of zonisamide","volume":"30","author":"Biton","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib263","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.expneurol.2018.07.005","article-title":"The anti-parkinsonian drug zonisamide reduces neuroinflammation: role of microglial Nav 1.6","volume":"308","author":"Hossain","year":"2018","journal-title":"Exp Neurol"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.03.035_bib264","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-022-01747-7","article-title":"Newly approved and investigational drugs for motor symptom control in Parkinson\u2019s disease","volume":"82","author":"Di Luca","year":"2022","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib265","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3233\/JPD-149001","article-title":"Is exenatide the next big thing in Parkinson\u2019s disease?","volume":"4","author":"Simuni","year":"2014","journal-title":"J Parkinsons Dis"},{"issue":"10103","key":"10.1016\/bs.pmbts.2024.03.035_bib266","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib267","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jnr.21483","article-title":"Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson\u2019s disease","volume":"86","author":"Bertilsson","year":"2008","journal-title":"J Neurosci Res"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib268","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-047993","article-title":"Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson\u2019s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: the \u2019Exenatide-PD3\u2019 study","volume":"11","author":"Vijiaratnam","year":"2021","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.03.035_bib269","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson\u2019s disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib270","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1586\/14737175.4.4.581","article-title":"Ropinirole therapy for Parkinson\u2019s disease","volume":"4","author":"Pahwa","year":"2004","journal-title":"Expert Rev Neurother"},{"issue":"46","key":"10.1016\/bs.pmbts.2024.03.035_bib271","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027653","article-title":"The effect and safety of ropinirole in the treatment of Parkinson disease: a systematic review and meta-analysis","volume":"100","author":"Zhu","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib272","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1527-3458.2005.tb00046.x","article-title":"Ropinirole, a non-ergoline dopamine agonist","volume":"11","author":"Jost","year":"2005","journal-title":"CNS Drug Rev"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib273","first-page":"179","article-title":"A review of ropinirole prolonged release in Parkinson\u2019s disease.","volume":"4","author":"Nashatizadeh","year":"2009","journal-title":"Clin Interv Aging"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib274","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/WNF.0b013e318255838b","article-title":"Selegiline: a reappraisal of its role in Parkinson disease","volume":"35","author":"Fabbrini","year":"2012","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib275","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jnr.10148","article-title":"Neuroprotective actions of selegiline","volume":"67","author":"Ebadi","year":"2002","journal-title":"J Neurosci Res"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib276","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0014-2999(84)90700-3","article-title":"Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys","volume":"106","author":"Cohen","year":"1984","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib277","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/j.1471-4159.1986.tb01747.x","article-title":"Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl","volume":"46","author":"Riederer","year":"1986","journal-title":"J Neurochem"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib278","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00702-019-02082-0","article-title":"Selegiline: a molecule with innovative potential","volume":"127","author":"T\u00e1bi","year":"2020","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib279","doi-asserted-by":"crossref","first-page":"1134472","DOI":"10.3389\/fnagi.2023.1134472","article-title":"Efficacy and safety of selegiline for the treatment of Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"15","author":"Wang","year":"2023","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib280","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2047-9158-2-19","article-title":"Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson\u2019s disease","volume":"2","author":"Teo","year":"2013","journal-title":"Transl Neurodegener"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.03.035_bib281","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2165\/11585090-000000000-00000","article-title":"Role of pramipexole in the management of Parkinson\u2019s disease","volume":"24","author":"Antonini","year":"2010","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib282","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/NDT.S2325","article-title":"Update on the use of pramipexole in the treatment of Parkinson\u2019s disease.","volume":"4","author":"Constantinescu","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib283","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.arcmed.2021.06.007","article-title":"Effect of pramipexole on inflammatory response in central nervous system of Parkinson\u2019s disease rat model","volume":"53","author":"Jiang","year":"2022","journal-title":"Arch Med Res"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib284","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12883-022-02830-y","article-title":"Efficacy of pramipexole on quality of life in patients with Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"22","author":"Li","year":"2022","journal-title":"BMC Neurol"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib285","first-page":"CD002261","article-title":"Pramipexole for levodopa-induced complications in Parkinson\u2019s disease","volume":"2000","author":"Clarke","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib286","first-page":"97","article-title":"Istradefylline for off episodes in Parkinson\u2019s disease: a US perspective of common clinical scenarios","volume":"12","author":"Isaacson","year":"2022","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib287","doi-asserted-by":"crossref","first-page":"32","DOI":"10.9740\/mhc.2022.01.032","article-title":"Istradefylline: a novel agent in the treatment of \u201coff\u201d episodes associated with levodopa\/carbidopa use in Parkinson disease","volume":"12","author":"Cummins","year":"2022","journal-title":"Ment Health Clin"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib288","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/neurolint12030017","article-title":"Istradefylline to treat patients with Parkinson\u2019s disease experiencing \"Off\" episodes: a comprehensive review","volume":"12","author":"Berger","year":"2020","journal-title":"Neurol Int"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib289","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.3233\/JPD-212672","article-title":"Efficacy of istradefylline, an Adenosine A2A receptor antagonist, as adjunctive therapy to levodopa in Parkinson\u2019s disease: a pooled analysis of 8 phase 2b\/3 Trials","volume":"11","author":"Hauser","year":"2021","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib291","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fpsyt.2010.00136","article-title":"Anti-inflammatory impact of minocycline in a mouse model of tauopathy","volume":"1","author":"Garwood","year":"2010","journal-title":"Front Psychiatry"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.03.035_bib292","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.3390\/ijms24065250","article-title":"Minocycline as treatment for psychiatric and neurological conditions: a systematic review and meta-analysis","volume":"24","author":"Panizzutti","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib293","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212553","article-title":"The therapeutic role of minocycline in Parkinson\u2019s disease","volume":"8","author":"Cankaya","year":"2019","journal-title":"Drugs Context"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib294","first-page":"545","article-title":"Tetrabenazine in the treatment of Huntington\u2019s disease","volume":"3","author":"Paleacu","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib295","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/TCRM.S17152","article-title":"Management of Huntington\u2019s disease: role of tetrabenazine.","volume":"7","author":"de Tommaso","year":"2011","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.03.035_bib296","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00002826-200211000-00003","article-title":"Tetrabenazine treatment for Huntington\u2019s disease-associated chorea","volume":"25","author":"Ondo","year":"2002","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.03.035_bib297","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1345\/aph.1M582","article-title":"Role of tetrabenazine for Huntington\u2019s disease-associated chorea","volume":"44","author":"Poon","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib298","doi-asserted-by":"crossref","unstructured":"Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group\/TETRA-HD Investigators. [published correction appears in BMC Neurol. 2011;11:18]. BMC Neurol. 2009;9:62. Published 2009 Dec 18. https:\/\/doi.org\/10.1371\/annotation\/dd60f248-ca3f-4824-a3b4-c07aefb1c7c310.1186\/1471-2377-9-62 PMID: 20021666.","DOI":"10.1186\/1471-2377-9-62"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.03.035_bib299","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1034\/j.1600-0404.2002.01197.x","article-title":"Olanzapine in Huntington\u2019s disease","volume":"105","author":"Paleacu","year":"2002","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib300","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/mdc3.12706","article-title":"Comparing risperidone and olanzapine to tetrabenazine for the management of chorea in Huntington disease: an analysis from the Enroll-HD database","volume":"6","author":"Schultz","year":"2018","journal-title":"Mov Disord Clin Pract"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib301","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00004714-200104000-00023","article-title":"Olanzapine and Huntington\u2019s disease","volume":"21","author":"Bogelman","year":"2001","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib302","first-page":"69","article-title":"Short-term effects of olanzapine in Huntington disease","volume":"14","author":"Squitieri","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib303","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002826-200209000-00007","article-title":"Olanzapine for Huntington\u2019s disease: an open label study","volume":"25","author":"Bonelli","year":"2002","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.03.035_bib304","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/ajhp\/55.10.1003","article-title":"Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy","volume":"55","author":"Bever","year":"1998","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib305","doi-asserted-by":"crossref","DOI":"10.1177\/11795735221092517","article-title":"Current and possible future therapeutic options for Huntington\u2019s Disease","volume":"14","author":"Ferguson","year":"2022","journal-title":"J Cent Nerv Syst Dis"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib306","first-page":"202","article-title":"Olanzapine in the management of psychosis in Huntington\u2019s disease: a case report.","volume":"47","author":"Huarcaya-Victoria","year":"2019","journal-title":"Actas Esp Psiquiatr"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib307","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110296","article-title":"Neuropharmacological effect of risperidone: from chemistry to medicine","volume":"369","author":"Bhat","year":"2023","journal-title":"Chem Biol Interact"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib308","first-page":"116","article-title":"Risperidone in the management of psychiatric and neurodegenerative disease in the elderly: an update","volume":"37","author":"DeVane","year":"2003","journal-title":"Psychopharmacol Bull"},{"issue":"43","key":"10.1016\/bs.pmbts.2024.03.035_bib309","doi-asserted-by":"crossref","first-page":"13730","DOI":"10.1523\/JNEUROSCI.4172-09.2009","article-title":"Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission?","volume":"29","author":"Ito","year":"2009","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib310","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4088\/JCP.v64n0205","article-title":"A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia","volume":"64","author":"Brodaty","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib311","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/026988119601000213","article-title":"A comparative trial use of sulpiride and risperidone in Huntington\u2019s disease: a pilot study","volume":"10","author":"Reveley","year":"1996","journal-title":"J Psychopharmacol"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib312","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1176\/jnp.8.3.338","article-title":"Sertraline in the treatment of severe aggressiveness in Huntington\u2019s disease","volume":"8","author":"Ranen","year":"1996","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.03.035_bib313","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3390\/brainsci7080093","article-title":"Selective serotonin reuptake inhibitors for treating neurocognitive and neuropsychiatric disorders following traumatic brain injury: an evaluation of current evidence","volume":"7","author":"Yue","year":"2017","journal-title":"Brain Sci"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib314","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.nbd.2008.01.015","article-title":"Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington\u2019s disease","volume":"30","author":"Duan","year":"2008","journal-title":"Neurobiol Dis"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib315","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.expneurol.2007.10.015","article-title":"The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6\/2 Huntington\u2019s disease mouse model","volume":"210","author":"Peng","year":"2008","journal-title":"Exp Neurol"},{"issue":"11","key":"10.1016\/bs.pmbts.2024.03.035_bib316","doi-asserted-by":"crossref","first-page":"22558","DOI":"10.3390\/ijms141122558","article-title":"Neuroprotective effects of psychotropic drugs in Huntington\u2019s disease","volume":"14","author":"Lauterbach","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.03.035_bib317","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s11940-013-0219-8","article-title":"Treatment of huntington disease","volume":"15","author":"Videnovic","year":"2013","journal-title":"Curr Treat Options Neurol"},{"issue":"29","key":"10.1016\/bs.pmbts.2024.03.035_bib318","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.2174\/1568026616666160608084834","article-title":"Dopamine targeting drugs for the treatment of schizophrenia: past, present and future","volume":"16","author":"Li","year":"2016","journal-title":"Curr Top Med Chem"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.03.035_bib319","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/jnnp.47.8.848","article-title":"Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington\u2019s disease","volume":"47","author":"Girotti","year":"1984","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.03.035_bib320","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1212\/WNL.35.10.1450","article-title":"The gait abnormality of Huntington\u2019s disease","volume":"35","author":"Koller","year":"1985","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib321","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.bbrc.2013.12.034","article-title":"Baclofen, a GABAB receptor agonist, enhances ubiquitin-proteasome system functioning and neuronal survival in Huntington\u2019s disease model mice","volume":"443","author":"Kim","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib322","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ana.410250308","article-title":"A controlled clinical trial of baclofen as protective therapy in early Huntington\u2019s disease","volume":"25","author":"Shoulson","year":"1989","journal-title":"Ann Neurol"},{"issue":"5802","key":"10.1016\/bs.pmbts.2024.03.035_bib323","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/290149a0","article-title":"3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABA B sites in rat brain","volume":"290","author":"Hill","year":"1981","journal-title":"Nature"},{"issue":"13","key":"10.1016\/bs.pmbts.2024.03.035_bib324","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib325","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1471-4159.1979.tb04516.x","article-title":"Baclofen: effects on amino acid release and metabolism in slices of guinea pig cerebral cortex","volume":"32","author":"Potashner","year":"1979","journal-title":"J Neurochem"},{"issue":"11","key":"10.1016\/bs.pmbts.2024.03.035_bib326","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s11910-013-0394-8","article-title":"Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects","volume":"13","author":"Linker","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib327","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ana.26555","article-title":"Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome","volume":"93","author":"Okuda","year":"2023","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib328","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1038\/s41467-019-11139-3","article-title":"Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes","volume":"10","author":"Carlstr\u00f6m","year":"2019","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.03.035_bib329","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.clinthera.2017.06.012","article-title":"Efficacy and safety of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis in prior interferon users: an integrated analysis of DEFINE and CONFIRM","volume":"39","author":"Fern\u00e1ndez","year":"2017","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib330","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1212\/CPJ.0b013e318296f10f","article-title":"Dimethyl fumarate for relapsing MS","volume":"3","author":"Serra","year":"2013","journal-title":"Neurol Clin Pract"},{"issue":"18","key":"10.1016\/bs.pmbts.2024.03.035_bib331","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s40265-019-01229-3","article-title":"Dimethyl fumarate: a review in relapsing-remitting MS","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.03.035_bib332","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/00023210-200418060-00010","article-title":"Mitoxantrone: a review of its use in multiple sclerosis","volume":"18","author":"Scott","year":"2004","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib333","first-page":"CD002127","article-title":"Mitoxantrone for multiple sclerosis","author":"Martinelli Boneschi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"1\u20132","key":"10.1016\/bs.pmbts.2024.03.035_bib334","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.pharmthera.2005.07.002","article-title":"Therapeutic role of mitoxantrone in multiple sclerosis","volume":"109","author":"Neuhaus","year":"2006","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib335","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1212\/01.wnl.0000174439.70369.7a","article-title":"Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial","volume":"65","author":"Krapf","year":"2005","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib336","first-page":"74","article-title":"Mitoxantrone in the treatment of multiple sclerosis","volume":"12","author":"Morrissey","year":"2005","journal-title":"Int MS J"},{"issue":"9350","key":"10.1016\/bs.pmbts.2024.03.035_bib337","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.03.035_bib338","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1080\/13543784.2016.1221924","article-title":"Ibudilast for the treatment of multiple sclerosis","volume":"25","author":"Goodman","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.03.035_bib339","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1177\/13524585231187289","article-title":"Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis","volume":"29","author":"Nakamura","year":"2023","journal-title":"Mult Scler"},{"issue":"9","key":"10.1016\/bs.pmbts.2024.03.035_bib340","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJMoa1803583","article-title":"Phase 2 trial of ibudilast in progressive multiple sclerosis","volume":"379","author":"Fox","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.03.035_bib341","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov Disord"},{"issue":"13","key":"10.1016\/bs.pmbts.2024.03.035_bib342","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1212\/WNL.0b013e3181d7d651","article-title":"Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?","volume":"74","author":"Barkhof","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib343","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/acn3.51251","article-title":"Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype","volume":"8","author":"Goodman","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib344","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00063030-199809050-00006","article-title":"Cladribine: a review of its use in multiple sclerosis","volume":"9","author":"Langtry","year":"1998","journal-title":"BioDrugs"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib345","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585211012227","article-title":"Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres","volume":"28","author":"Pfeuffer","year":"2022","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib346","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40263-019-00604-8","article-title":"Correction to: cladribine tablets: a review in relapsing MS","volume":"33","author":"Deeks","year":"2019","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.03.035_bib347","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib348","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib349","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/WNF.0000000000000552","article-title":"Safety and effectiveness of cladribine in multiple sclerosis: real-world clinical experience from 5 tertiary hospitals in portugal","volume":"46","author":"Santos","year":"2023","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib350","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1756285614546855","article-title":"Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects","volume":"7","author":"Oh","year":"2014","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib351","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2217\/nmt-2021-0014","article-title":"An updated review of teriflunomide\u2019s use in multiple sclerosis","volume":"11","author":"Miller","year":"2021","journal-title":"Neurodegener Dis Manag"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib352","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/nmt-2016-0029","article-title":"Teriflunomide in multiple sclerosis: an update","volume":"7","author":"Miller","year":"2017","journal-title":"Neurodegener Dis Manag"},{"issue":"14","key":"10.1016\/bs.pmbts.2024.03.035_bib353","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O\u2019Connor","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib354","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib355","first-page":"CD009882","article-title":"Teriflunomide for multiple sclerosis","volume":"3","author":"He","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.03.035_bib356","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1080\/13548506.2021.1931371","article-title":"The role of teriflunomide in Multiple Sclerosis patient: an observational study","volume":"27","author":"Corallo","year":"2022","journal-title":"Psychol Health Med"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib357","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2147\/NDT.S114636","article-title":"The use of natalizumab for multiple sclerosis","volume":"13","author":"Brandstadter","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib358","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103995","article-title":"Use of natalizumab in persons with multiple sclerosis: 2022 update","volume":"65","author":"Morrow","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib399","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1083\/jcb.201207175","article-title":"The discovery of natalizumab, a potent therapeutic for multiple sclerosis","volume":"199","author":"Steinman","year":"2012","journal-title":"J Cell Biol"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib359","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.bbadis.2015.10.018","article-title":"Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke","volume":"1862","author":"Lopes Pinheiro","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib360","first-page":"189","article-title":"Natalizumab for the treatment of relapsing multiple sclerosis","volume":"2","author":"Rudick","year":"2008","journal-title":"Biologics"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.03.035_bib361","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a mini review","volume":"10","author":"Fayyaz","year":"2018","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib362","first-page":"CD004678","article-title":"Glatiramer acetate for multiple sclerosis","author":"La Mantia","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.03.035_bib363","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2165\/00023210-200216120-00004","article-title":"Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis","volume":"16","author":"Simpson","year":"2002","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.03.035_bib364","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/nedt.2007.3.2.259","article-title":"Glatiramer acetate in the treatment of multiple sclerosis","volume":"3","author":"Tselis","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.03.035_bib365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066772","article-title":"CD8(+) T cells are required for glatiramer acetate therapy in autoimmune demyelinating disease.","volume":"8","author":"Tyler","year":"2013","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/bs.pmbts.2024.03.035_bib366","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2165\/00002018-200124130-00005","article-title":"Risk-benefit assessment of glatiramer acetate in multiple sclerosis","volume":"24","author":"Ziemssen","year":"2001","journal-title":"Drug Saf"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib367","first-page":"261","article-title":"Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations","volume":"12","author":"Ayzenberg","year":"2016","journal-title":"Ther Clin Risk Manag"},{"issue":"11","key":"10.1016\/bs.pmbts.2024.03.035_bib368","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s40263-020-00771-z","article-title":"Siponimod: a review in secondary progressive multiple sclerosis","volume":"34","author":"Scott","year":"2020","journal-title":"CNS Drugs"},{"issue":"1\u20132","key":"10.1016\/bs.pmbts.2024.03.035_bib369","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jns.2013.02.011","article-title":"Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy","volume":"328","author":"Groves","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib370","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fncel.2014.00283","article-title":"Fingolimod for the treatment of neurological diseases-state of play and future perspectives","volume":"8","author":"Brunkhorst","year":"2014","journal-title":"Front Cell Neurosci"},{"issue":"20","key":"10.1016\/bs.pmbts.2024.03.035_bib371","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.3390\/jcm11206033","article-title":"Disease reactivation in secondary progressive multiple sclerosis patients switching from fingolimod to siponimod: a case series","volume":"11","author":"Abbadessa","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib372","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.07.011","article-title":"Early initiation of fingolimod reduces the rate of severe relapses over the long term: post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies","volume":"36","author":"Haas","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"10127","key":"10.1016\/bs.pmbts.2024.03.035_bib373","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/bs.pmbts.2024.03.035_bib374","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s40265-017-0814-1","article-title":"Benefit-Risk profile of Sphingosine-1-phosphate receptor modulators in relapsing and secondary progressive multiple sclerosis","volume":"77","author":"Comi","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib375","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114378","article-title":"Masitinib: the promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series","volume":"160","author":"Ketabforoush","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.03.035_bib376","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001148","article-title":"Efficacy and safety of masitinib in progressive forms of multiple sclerosis: a randomized, Phase 3, clinical trial","volume":"9","author":"Vermersch","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib377","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211030365","article-title":"Long-term survival analysis of masitinib in amyotrophic lateral sclerosis","volume":"14","author":"Mora","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib378","article-title":"Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence","author":"Hamad","year":"2023","journal-title":"Neurol Sci"},{"issue":"1\u20132","key":"10.1016\/bs.pmbts.2024.03.035_bib379","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/21678421.2019.1672750","article-title":"Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis","volume":"21","author":"Babu","year":"2020","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"22","key":"10.1016\/bs.pmbts.2024.03.035_bib380","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000020423","article-title":"Tamoxifen for amyotrophic lateral sclerosis: a randomized double-blind clinical trial","volume":"99","author":"Chen","year":"2020","journal-title":"Med (Baltim)"},{"issue":"20","key":"10.1016\/bs.pmbts.2024.03.035_bib381","doi-asserted-by":"crossref","first-page":"15430","DOI":"10.3390\/ijms242015430","article-title":"The key role of astrocytes in amyotrophic lateral sclerosis and their commitment to glutamate excitotoxicity","volume":"24","author":"Provenzano","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib382","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2826.2011.02156.x","article-title":"Selective oestrogen receptor modulators decrease the inflammatory response of glial cells","volume":"24","author":"Arevalo","year":"2012","journal-title":"J Neuroendocrinol"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib383","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/ijms25010458","article-title":"Tamoxifen activates transcription Factor EB and triggers protective autophagy in breast cancer cells by inducing lysosomal calcium release: a gateway to the onset of endocrine resistance","volume":"25","author":"Boretto","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/bs.pmbts.2024.03.035_bib384","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.3390\/cells9112413","article-title":"Amyotrophic\u00a0lateral sclerosis and autophagy: dysfunction and therapeutic targeting","volume":"9","author":"Amin","year":"2020","journal-title":"Cells"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib385","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1474-4422(18)30054-1","article-title":"Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study","volume":"17","author":"Fang","year":"2018","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.03.035_bib386","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2217\/nmt-2020-0033","article-title":"Riluzole for the treatment of amyotrophic lateral sclerosis","volume":"10","author":"Saitoh","year":"2020","journal-title":"Neurodegener Dis Manag"},{"issue":"6 Suppl 4","key":"10.1016\/bs.pmbts.2024.03.035_bib387","first-page":"S233","article-title":"The pharmacology and mechanism of action of riluzole","volume":"47","author":"Doble","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib388","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.neuropharm.2018.09.021","article-title":"Riluzole attenuates the efficacy of glutamatergic transmission by interfering with the size of the readily releasable neurotransmitter pool","volume":"143","author":"Lazarevic","year":"2018","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib389","first-page":"25","article-title":"Edaravone (Radicava): a novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis","volume":"43","author":"Cruz","year":"2018","journal-title":"P T"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.03.035_bib390","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13024-021-00510-y","article-title":"Edaravone activates the GDNF\/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells","volume":"17","author":"Li","year":"2022","journal-title":"Mol Neurodegener"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.03.035_bib391","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258614","article-title":"Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]","volume":"17","author":"Brooks","year":"2022","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.03.035_bib392","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3390\/ijms23052400","article-title":"Comprehensive research on past and future therapeutic strategies devoted to treatment of amyotrophic lateral sclerosis","volume":"23","author":"Sever","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/bs.pmbts.2024.03.035_bib393","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1474-4422(14)70222-4","article-title":"Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial","volume":"13","author":"Cudkowicz","year":"2014","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.03.035_bib394","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1002\/jcp.22609","article-title":"Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics","volume":"226","author":"Kim","year":"2011","journal-title":"J Cell Physiol"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.03.035_bib395","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1089\/ars.2009.2444","article-title":"Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis","volume":"11","author":"Foran","year":"2009","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/bs.pmbts.2024.03.035_bib396","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.661412","article-title":"The Effect of GLT-1 upregulation on extracellular glutamate dynamics","volume":"15","author":"Wilkie","year":"2021","journal-title":"Front Cell Neurosci"},{"issue":"7021","key":"10.1016\/bs.pmbts.2024.03.035_bib397","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nature03180","article-title":"Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression","volume":"433","author":"Rothstein","year":"2005","journal-title":"Nature"}],"container-title":["Progress in Molecular Biology and Translational Science","Clinical Application of Repurposed Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117324000905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117324000905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:11:37Z","timestamp":1753355497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117324000905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443241147"],"references-count":399,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2024.03.035","relation":{},"ISSN":["1877-1173"],"issn-type":[{"type":"print","value":"1877-1173"}],"subject":[],"published":{"date-parts":[[2024]]}}}